ACell (Columbia, Md.) announced that it has signed an exclusive distribution agreement with MyungMoon Bio to market ACell’s wound matrix devices in South Korea.
“South Korea is one of the largest healthcare markets in the Asia Pacific, and this agreement will meet a growing unmet need for innovative wound management solutions in the country,” Nino Pionati, VP of international and business development for ACell, said in a press release. “We are excited about this partnership, and the opportunity to bring ACell’s regenerative products to the patients and clinicians of South Korea.”
Through the agreement, MyungMoon Bio has the exclusive rights to sell, market and distribute ACell’s MicroMatrix and Cytal Wound Matrix devices in South Korea. MyungMoon will also work with ACell to get regulatory clearance.
“Our Cytal and MicroMatrix wound management devices facilitate remodeling of healthy, functional tissue in a range of complex and hard-to-heal wounds,” Patrick McBrayer, CEO of ACell, said. “This agreement expands access to these products even further across the globe, and continues ACell’s path towards becoming the global leaders in complex wound care.”
MyungMoon Bio is a manufacturer and distributor of medical device and pharmaceutical products in South Korea. It is currently developing medicines and medical supplies for treating incurable diseases.
“MyungMoon Bio is very fortunate to become a business partner of ACell, which is opening new horizons in regenerative medicine. MyungMoon Bio, equipped with solid organization and sales capacity in the South Korean market, will lay the groundwork for ACell to achieve early success in the Asian region,” Sha-Joung Chang, president of MyungMoon Bio, said.